IS2596B - 1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa - Google Patents

1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa

Info

Publication number
IS2596B
IS2596B IS6590A IS6590A IS2596B IS 2596 B IS2596 B IS 2596B IS 6590 A IS6590 A IS 6590A IS 6590 A IS6590 A IS 6590A IS 2596 B IS2596 B IS 2596B
Authority
IS
Iceland
Prior art keywords
fusion
farnesyl transferase
inhibits farnesyl
quinoline enantiomer
enantiomer
Prior art date
Application number
IS6590A
Other languages
English (en)
Icelandic (is)
Other versions
IS6590A (is
Inventor
David William End
Marc Gaston Venet
Patrick Rene Angibaud
Original Assignee
Janssen Pharmaceutica N V Patent Dept
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N V Patent Dept filed Critical Janssen Pharmaceutica N V Patent Dept
Publication of IS6590A publication Critical patent/IS6590A/is
Publication of IS2596B publication Critical patent/IS2596B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS6590A 2000-06-22 2002-10-25 1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa IS2596B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (2)

Publication Number Publication Date
IS6590A IS6590A (is) 2002-10-25
IS2596B true IS2596B (is) 2010-03-15

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6590A IS2596B (is) 2000-06-22 2002-10-25 1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa

Country Status (33)

Country Link
US (3) US20030114471A1 (enExample)
EP (1) EP1296984B1 (enExample)
JP (1) JP4919575B2 (enExample)
KR (2) KR100831940B1 (enExample)
CN (1) CN1207296C (enExample)
AR (1) AR030704A1 (enExample)
AT (1) ATE294804T1 (enExample)
AU (3) AU6396201A (enExample)
BG (1) BG65894B1 (enExample)
BR (1) BRPI0111743B8 (enExample)
CA (1) CA2410232C (enExample)
CZ (1) CZ295278B6 (enExample)
DE (1) DE60110592T2 (enExample)
EA (1) EA005065B1 (enExample)
EE (1) EE04966B1 (enExample)
EG (1) EG24180A (enExample)
ES (1) ES2241830T3 (enExample)
HR (1) HRP20020989B1 (enExample)
HU (1) HU229095B1 (enExample)
IL (2) IL153560A0 (enExample)
IS (1) IS2596B (enExample)
JO (1) JO2361B1 (enExample)
MX (1) MXPA02012845A (enExample)
MY (1) MY127734A (enExample)
NO (1) NO324494B1 (enExample)
NZ (1) NZ522481A (enExample)
PA (1) PA8519501A1 (enExample)
PL (1) PL209521B1 (enExample)
SA (1) SA01220349B1 (enExample)
SK (1) SK285699B6 (enExample)
UA (1) UA73572C2 (enExample)
WO (1) WO2001098302A1 (enExample)
ZA (1) ZA200210305B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ES2271574T3 (es) 2002-04-15 2007-04-16 Janssen Pharmaceutica N.V. Derivados triciclicos de quinazolina inhibidores de la farnesiltransferasa, sustituidos con imidazoles o triazoles enlazados al carbono.
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
DK3285768T3 (da) 2015-04-21 2021-01-25 Eiger Biopharmaceuticals Inc Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir
HUE057306T2 (hu) 2015-08-17 2022-04-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
TW201818965A (zh) 2016-11-03 2018-06-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
SI1162201T1 (sl) * 1995-12-08 2006-08-31 Janssen Pharmaceutica Nv (Imidazol-5-il)metil-2-kinolinonski derivati kot inhibitorji farnezil protein transferaze
JP2000507955A (ja) 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
KR100520401B1 (ko) * 1997-04-25 2005-10-12 얀센 파마슈티카 엔.브이. 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논
ATE222104T1 (de) 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
PT1094839E (pt) * 1998-07-06 2003-09-30 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase com propriedades de radiossensibilizacao (in vivo)
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ES2259237T3 (es) * 1998-08-27 2006-09-16 Pfizer Products Inc. Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
AU4925199A (en) * 1998-08-27 2000-03-21 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
EA004542B1 (ru) * 1998-12-23 2004-06-24 Янссен Фармацевтика Н.В. 1, 2-аннелированные производные хинолина
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
AU2124800A (en) * 1999-02-11 2000-08-29 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (en) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
EP1322644A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives

Also Published As

Publication number Publication date
BR0111743A (pt) 2003-07-08
NO20026032L (no) 2002-12-16
CZ2003114A3 (cs) 2003-05-14
AU2006220405A1 (en) 2006-10-12
KR100831940B1 (ko) 2008-05-23
AU2006220405B2 (en) 2009-05-21
UA73572C2 (en) 2005-08-15
CN1437601A (zh) 2003-08-20
HUP0300872A2 (hu) 2003-07-28
EA005065B1 (ru) 2004-10-28
EP1296984A1 (en) 2003-04-02
US8329714B2 (en) 2012-12-11
IL153560A (en) 2011-06-30
NO20026032D0 (no) 2002-12-16
CN1207296C (zh) 2005-06-22
MXPA02012845A (es) 2003-05-15
AR030704A1 (es) 2003-09-03
PL209521B1 (pl) 2011-09-30
BG65894B1 (bg) 2010-04-30
IS6590A (is) 2002-10-25
SK285699B6 (sk) 2007-06-07
EE04966B1 (et) 2008-02-15
HU229095B1 (en) 2013-07-29
IL153560A0 (en) 2003-07-06
EE200200695A (et) 2004-06-15
SA01220349B1 (ar) 2007-01-23
HRP20020989A2 (en) 2005-02-28
HK1058363A1 (en) 2004-05-14
PL358918A1 (en) 2004-08-23
EA200300048A1 (ru) 2003-04-24
EG24180A (en) 2008-09-28
CA2410232A1 (en) 2001-12-27
DE60110592T2 (de) 2006-01-19
ES2241830T3 (es) 2005-11-01
JP4919575B2 (ja) 2012-04-18
WO2001098302A1 (en) 2001-12-27
SK502003A3 (en) 2003-05-02
BG107310A (bg) 2003-07-31
AU6396201A (en) 2002-01-02
KR20030009463A (ko) 2003-01-29
CA2410232C (en) 2008-10-07
ATE294804T1 (de) 2005-05-15
US20070259902A1 (en) 2007-11-08
HRP20020989B1 (hr) 2011-05-31
EP1296984B1 (en) 2005-05-04
US20080114009A1 (en) 2008-05-15
US20030114471A1 (en) 2003-06-19
NO324494B1 (no) 2007-10-29
AU2001263962B2 (en) 2006-07-20
KR100846370B1 (ko) 2008-07-15
ZA200210305B (en) 2004-03-19
CZ295278B6 (cs) 2005-06-15
KR20070121847A (ko) 2007-12-27
BRPI0111743B1 (pt) 2019-03-26
MY127734A (en) 2006-12-29
US8318753B2 (en) 2012-11-27
BRPI0111743B8 (pt) 2021-05-25
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
NZ522481A (en) 2004-09-24
JO2361B1 (en) 2006-12-12
HUP0300872A3 (en) 2004-11-29
PA8519501A1 (es) 2002-08-29

Similar Documents

Publication Publication Date Title
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MXPA02005844A (es) Inhibidores de cinasas de proteina.
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
IS2596B (is) 1,2-samrunnin qínólín handhverfa sem tálmar farnesýl transferasa
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
WO2001060458A3 (en) Inhibitors of prenyl-protein transferase
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
SE0102887D0 (sv) New formulation
MY122477A (en) Sertraline oral concentrate